Streetbeat News

Revenues

IRWD

Ironwood Pharmaceuticals has reaffirmed its FY23 revenue outlook of $435M-$450M, which is in line with the estimated $441.42M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:04 pm

DM

Desktop Metals has projected its FY23 revenue to be between $187M and $207M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:32 am

AVAH

Aveanna Healthcare has raised its sales outlook for FY2023 from $1.85B-$1.86B to $1.87B-$1.88B, against an estimate of $1.86B. The company also updated its Adjusted EBITDA guidance from $132M-$135M to $134M-$137M. However, it did not provide guidance on net income due to the volatility of certain required inputs.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:18 am

CIO

City Office REIT (CIO) reported Q3 in-place occupancy of 85.4% and executed approximately 119,000 square feet of new and renewal leases.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:18 am

FA

First Advantage has reiterated its 2023 guidance ranges, expecting results at the low end of ranges of $770M-$810M revenues and $1.00-$1.07 adjusted EPS. This is based on the current hiring environment and expectations that existing macroeconomic conditions and similar labor market trends will continue through the end of fiscal year 2023.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:13 am

GDRX

GoodRx has projected its FY23 adjusted revenue to be between $752M and $758M, which is in line with the consensus estimate of $754.94M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:09 am

EYE

National Vision has revised its 2023 net revenue forecast downwards from $2.075B-$2.135B to $2.115B-$2.125B.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:09 am

GRAB

Grab Holdings Inc. reported Q3 deliveries GMV of $2.61B, a 7% increase year-over-year, and Mobility GMV of $1.415B, a 30% increase year-over-year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:09 am

GRAB

Grab Holdings Inc. has raised its FY23 revenue outlook from $2.20B - $2.30B to $2.31B - $2.33B, slightly above the $2.32B estimate. The company also improved its adjusted EBITDA guidance from $(30) million - $(40) million to $(20) million - $(25) million.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:06 am

GDRX

GoodRx has projected its Q4 FY23 adjusted revenue to be between $188M and $194M, which is in line with the consensus estimate of $192.67M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:05 am